Fusion Pharmaceuticals Inc. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
270 Longwood Road South, Hamilton, Ontario, Canada
State of incorporation
Canada (Federal Level)
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2024 - May 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.22K % -14.6%
Debt-to-equity 32.2 % +15.8%
Return On Equity -33.9 % -43.1%
Return On Assets -36.9 % +4.58%
Operating Margin -4.8K % +20.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 84.9M shares +34.3%
Common Stock, Shares, Outstanding 84.9M shares +34.3%
Entity Public Float 302M USD +210%
Weighted Average Number of Shares Outstanding, Basic 83.8M shares +55.8%
Weighted Average Number of Shares Outstanding, Diluted 83.8M shares +55.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.07M USD +41.5%
Research and Development Expense 75.5M USD +21.6%
General and Administrative Expense 36.7M USD +17.9%
Operating Income (Loss) -110M USD -19.4%
Nonoperating Income (Expense) 6.52M USD +253%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -89.4M USD -10.2%
Income Tax Expense (Benefit) 561K USD -2055%
Net Income (Loss) Attributable to Parent -104M USD -13.4%
Earnings Per Share, Basic -1.4 USD/shares +29.6%
Earnings Per Share, Diluted -1.4 USD/shares +29.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 27.8M USD -48.2%
Other Assets, Current 432K USD -66.7%
Assets, Current 221M USD +0.13%
Deferred Income Tax Assets, Net 4.37M USD -17.6%
Property, Plant and Equipment, Net 6.58M USD +28.1%
Operating Lease, Right-of-Use Asset 17.9M USD +0.12%
Other Assets, Noncurrent 652K USD -88.1%
Assets 324M USD +21.5%
Accounts Payable, Current 2.5M USD +31.5%
Employee-related Liabilities, Current 2.61M USD +2.92%
Accrued Liabilities, Current 10.3M USD +66.9%
Liabilities, Current 20.8M USD +19.8%
Operating Lease, Liability, Noncurrent 10.6M USD -4.46%
Liabilities 82M USD +24.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -582K USD -585%
Retained Earnings (Accumulated Deficit) -410M USD -34.1%
Stockholders' Equity Attributable to Parent 242M USD +20.4%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 199M USD -24.5%
Liabilities and Equity 324M USD +21.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -27.3M USD -7.36%
Net Cash Provided by (Used in) Financing Activities 64M USD +7.55%
Net Cash Provided by (Used in) Investing Activities -70.4M USD -187%
Common Stock, Shares, Issued 84.9M shares +34.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -33.7M USD -452%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 29.1M USD -47%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.63M USD +48.6%
Deferred Tax Assets, Valuation Allowance 91.9M USD +35.6%
Deferred Tax Assets, Gross 101M USD +36%
Operating Lease, Liability 14.9M USD -5.37%
Payments to Acquire Property, Plant, and Equipment 1.33M USD +9.08%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -105M USD -14.5%
Lessee, Operating Lease, Liability, to be Paid 24.1M USD -10.3%
Property, Plant and Equipment, Gross 7.76M USD +17.3%
Operating Lease, Liability, Current 4.29M USD -7.55%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.4M USD -6.91%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.37M USD +8.06%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure -9.17%
Deferred Income Tax Expense (Benefit) -405K USD +18%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.19M USD -17.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.32M USD -43.5%
Unrecognized Tax Benefits 254K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.29M USD -2.72%
Operating Lease, Payments 973K USD +123%
Depreciation, Depletion and Amortization 361K USD +32.2%
Deferred Tax Assets, Net of Valuation Allowance 8.71M USD +40.8%
Share-based Payment Arrangement, Expense 13.8M USD +21.6%